Advisory Board and Editors Oncology
Jiangjiang Qin
Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).
Dr. Qin received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University, China, under the supervision of Professor Wei-Dong Zhang. After completion of Post-Doctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC) in 2014, Dr. Qin continued his research work at TTUHSC as a Research Associate and a Senior Research Associate and at the University of Houston as a Senior Research Scientist. Dr. Qin joined Zhejiang Chinese Medicinal University as a Full Professor in 2018 and then moved to IBMC in 2020.
Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 150 research papers and reviews. He is also an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an Editorial Board Member of more than 10 scientific journals such as Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research Updates, World Journal of Traditional Chinese Medicine.
Yasser Riazalhosseini
After undertaking post-doctoral studies on Cancer Genomics at the Deutsches Krebsforschungszentrum (DKFZ; German Cancer Research Centre), Yasser Riazalhosseini joined the Department of Human Genetics at McGill as an Assistant Professor, and was appointed Group Head of the Cancer Genomics program at the McGill University Genome Centre. His principal activity has been to initiate and lead a multidisciplinary, applied research program on cancer genomics, with the goals of obtaining better preventions and treatments. His research program uses systems biology approaches that combine genomics datasets involving sequences from hundreds of cancers coupled with detailed clinical data, and functional studies.
Camillo Rosano
A physicist; in 1996 Camillo Rosano started his studies in Macromolecular Crystallography at the Advanced Biotechnology Center, Genova (I). In 1997 he achieved the Advanced Certificate in Principles of Protein Structures (PPS), Birkbeck College, University of London, UK, and in 1998 he spent a period at the “York Structural Biology Laboratory” York University, York, UK for a Macromolecular crystallography traineeship. He participated to the NASA expeditions STS100/ISS6A and STS110/ISS7A by designing experiment of protein crystallization on-board the International Space Station (ISS). Director of different Courses and Workshops, he is the author/coauthor of more than 100 peer-reviewed scientific publications.
Dr. Rosano is a Full Professor in Biochemistry and Full Professor in Applied Biology. Italian Ministry for University, Education and Research (MIUR), 2012.
Rebecca H Roubin
Lecturer in Pharmaceutical and Medicinal Chemistry, University of Sydney
Member, Cancer Research Network
Past Vice-President, Sydney Tissue Engineering and Matrix (STEAM) interest group
Member, Antler Science and Product Technology Society International (ASPTS)
Member, Matrix Biology Society of Australia and New Zealand (MBSANZ)
Past-President, Royal North Shore Hospital Postgraduate Research Students’ Society
Stephen Rajan Samuel
Dr. Stephen Samuel is a leader in the field of exercise oncology. He is a Fulbright alumni, the past vice chair (2016-2020) & past chair (2020-2023) of the fatigue study group of the multinational association of supportive care in cancer (MASCC) and the recipient of the Young Investigator of the year in cancer award by MASCC in 2015.He is the program director and Associate Professor of Exercise Science at the Mount Vernon Nazarene University, Ohio, USA. Over the last one decade Dr. Samuel has published his work in exercise oncology in some of the highly reputed journals in collaboration with researchers from various parts of the world.
J. Thomas Sanderson
Professor of Toxicology at the INRS-Institut Armand-Frappier, Université du Québec, Laval, Canada. Adjunct professor at the Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montréal, Canada. Member and former councillor (2008-2011) of the Society of Toxicology of Canada. Member of the Society of Toxicology since 2000. Recipient of a 2006 Leader's Opportunities Fund Infrastructure Award from the Canadian Foundation for Innovation. Current research funded by the Canadian Institutes of Health Research and Natural Sciences and Engineering Council of Canada.
Darren N Saunders
Senior Lecturer in Medicine at the University of NSW and visiting fellow at the Kinghorn Cancer Centre, Garvan Institute in Sydney, Australia. Science communicator and past deputy chair of the Australian Academy of Science Early-Mid Career Researcher Forum. Australian Leadership Award (2012), NSW Life Scientist Research Award (2010).
My research is focused on proteostasis and metabolic reprogramming in cancer and neurodegeneration, integrating various platforms (including proteomics, genomics, and metabolomics) to better understand genotype-phenotype relationships. I have a long-standing interest in protein homeostasis (proteostasis), publishing numerous manuscripts providing mechanistic insights into serpin biology and the Ubiquitin-proteasome system, with more recent work aimed at characterising novel mutations involved in protein misfolding and Ub systems in various disease states. I developed a novel platform for screening protein-protein interactions in situ, and novel proteomics approaches to systematically identify E3 Ub ligase substrates and for exploring interactome diversity in cell signalling. We use a number of models systems including patient-derived iPS cells, patient derived tumour xenografts and transgenic models of cancer and neurodegeneration. I am also collaborating to develop creative technology-based approaches to visualizing and communicating complex data, using music to explore the intersection between genetics and environment.
Mirela Sedic
Dr Mirela Sedic (born Bauman) is Principal Scientist at the Institute for Anthropological Research Zagreb. She has authored over 50 scientific publications in peer-reviewed journals including high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Cancer Treatment Reviews.
She was the co-PI of international collaborative project with Functional Genomics Center Zurich in Switzerland (PRIME-XS-0000184 Proteomic profiling of retinal proteins from rat model of age-related macular degeneration 2012-2014) and the PI of the University of Rijeka grant “Screening and biological evaluation of acid ceramidase and sphingosine kinase inhibitors as a new class of anti-tumour agents” (2014 – 2017). She is currently the PI of the project funded by the Croatian Science Foundation “Dissecting the mechanisms of therapy resistance in BRAF-mutant colon cancer using an integrated –omics approach” (2019 – 2023) and the PI of the University of Rijeka research grant “Molecular features associated with BRAFV600E-mutated versus wild type BRAF colorectal cancer” (2019-2022). She is also the PI of the project No. 3238 - EPIC-XS 012: “Proteomic analysis of acquired resistance to vemurafenib in BRAF V600E–mutant colon cancer cells” (2019 - 2022) in collaboration with the Functional Genomics Center Zurich in Switzerland.
Jay Shah
Prof. Jay Shah is a Professor of Surgery at Patan Hospital, a tertiary care teaching hospital of health science university, ‘Patan
Academy of Health Sciences’, Lalitpur, Kathmandu, Nepal. He is responsible for managing and leading the unit in-charge of the surgery department, comprising of more than 30 faculties, residents, interns and medical students. His unit manages 3 outpatients and 3 operation theatre days a week.
Prof. Shah is involved in undergraduate and postgraduate teaching programs of the school of medicine, nursing, and public health.
In addition, he is also involved with the Primary Trauma Course (PTC), research, writing and publishing in scientific journals, and the post-graduate committee.
Huashan Shi
Professor Shi Huashan is an Associate Professor at Sichuan University. His expertise is in the molecular biology of tumours and tumour transcriptomics. He is currently engaged in clinical and basic translational research, including tumour microenvironment and novel immunotherapeutic modalities, and research on the mechanisms and medical applications related to tumour cell vaccines.
Paula Soares
Professor of Biopathology at Medical Faculty of the University of Porto and coordinator of Cancer Signaling and Metabolism research group at IPATIMUP/I3S.
Kumaravel Somasundaram
Kumar Somasundaram is a Professor at Department of Microbiology Cell Biology, Indian Institute of Science, Bangalore, India. He obtained his Veterinary Medicine degree (1985) from Madras Veterinary College, Masters in Biotechnology (1987) and Ph.D. in bacterial genetics (1993) from Madurai Kamaraj University, Madurai, India. Subsequently, he did his post-doctoral training at Northwestern University and University of Pennsylvania in Cancer Biology before moving to Indian Institute of Science (1999) as a faculty. The major focus of his laboratory is genetics of glioma, the most common primary adult cancer